Kangfang BioPD-1/VEGF dual anti-AK112 starts clinically.

From: Insight Database () AK112 is a dual anti-new drug developed by Kangfang Bio.
the target VEGF and PD-1, respectively, as regulatory factors and immune checkpoints for angiogenesics, which play an important role in tumor angiogenesic and immune escape.
AK112 combines PD-1 and VEGF with high affinity, has a dual mechanism of immuno checkpoint and anti-angiogenesign inhibition, thus enhancing anti-tumor activity more effectively.
Previously, the combination therapy of PD-1/PD-L1 antibodies and VEGF blockers has shown excellent results in a number of tumor indications, and has been approved in the United States tecentriq (Tershanqi, PD-L1 antibody) and Avastin (Avetin, VEGF blockers) for first-line treatment of hepatocellular and renal cell carcinoma.
approval is based on Phase III IMbrave150 clinical trials.
results showed that Tecentriq and Avastin reduced the patient's risk of death by 42% compared to the first-line therapy (HR=0.58; 95% CI: 0.42-0.79; p=) 0.0006), reducing the risk of disease deterioration or death by 41% (HR=0.59;95% CI:0.47-0.76;p<0.0001).
AK112 was approved for clinical use by the FDA in July 2019 and was first clinically launched in Australia, completing the first patient administration in September 2019.
asco annual meeting in 2020, Kangfang Bio announced the progress of its clinical study for the treatment of advanced solid tumor Phase I.
, according to insight database, Kangfang has two double anti-clinical stages, involving seven clinical trials.
in addition to this start-up clinical AK112, the target PD-1/CTLA4 dual anti-AK104 was launched in February 2019 Phase II clinical, with its same target in the study of dual resistance and Qilu QL1706, in Phase I clinical.
from: Insight Database ()